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1. Introduction 
Human err-antitrypsin (or-AT) has 3 carbohydrate 
sidechains [ 11. The attachment point of one of these 
sidechains has been determined in conjunction with 
the amino acid sequence of the C-terminal third of 
the molecule [2]. We now provide further sequence 
data which define the attachment points of the other 
2 carbohydrate sidechains. These data also show the 
extent of the sequence homology with antithrombin- 
III and ovalbumin, and provide support for a single 
reactive centre situated near the C-terminus. 
tryptic digestion in 2 M guanidine hydrochloride in 
0.1 M NI&HCOa buffer, pH 8.0 at 37’C for 15 h 
with an enzyme to substrate ratio of 1: 10. 
2. Methods 
The glycopeptides were separated from the bulk of 
the peptides by gel filtration on Sephadex G-50 in 
0.05 M NH4HC0a. Ion-exchange chromatography on 
DEAE-A25 Sephadex in 0.02 M Tris-HCl (pH 8.1) 
buffer with a linear gradient of O-O.5 M NaCl resolved 
the 3 tryptic glycopeptides. A final step of affinity 
chromatography on concanavalin A-Sepharose 4B 
was performed as described for the pronase glycopep- 
tides in [6] to remove minor peptide contaminants. 
This step also gave an indication of the ratio of bian- 
tennary to triantennary oligosaccharide chains for 
each glycopeptide. 
Human or-AT was isolated from plasma by thiol 
exchange [3]. Cyanogen bromide fragments were 
prepared and isolated as in [4]. Automated sequence 
analysis was carried out in a Beckman 890 C sequena- 
tor using the 1 M quadrol program. PTH derivatives 
were identified by high-performance liquid chroma- 
tography and by back hydrolysis with HI. 
Sequences were aligned for maximum homology 
using the Needleman-Wunsch algorithm with the 
MDM,a score matrix [7]; gap penalty and matrix bias 
parameters were 100 and 60, respectively. The statis- 
tical significance of homology was tested by compari- 
son with match scores for 100 randomisations of the 
sequences generated by selection with replacement. 
Subpeptide digestion was carried out as in [S] 
using trypsin, chymotrypsin, thermolysin or Staphylo- 
cocc~saureus V8 protease. Enzyme to substrate ratios 
of I:30 were used with digestion at pH 8.6 in 0.1 M 
NH4HC0a buffer. Peptide isolation and dansyl-Edman 
sequence determinations were performed as in [5]. 
3. Results and discussion 
Standard tryptic digestion ofheat denatured or-AT 
yielded the central and C-terminal glycopeptides but 
not the N-terminal glycopeptide centred on Asn 46. 
This was obtained by denaturation of or-AT in 6 M 
guanidine hydrochloride at 70°C for 2 h, followed by 
Abbreviations: q-AT, cY,-antitrypsin;PTH, phenylthiohydantoin 
Analysis of the individual glycopeptides and of the 
cyanogen bromide fragments of the whole molecule 
confirmed the finding [I] that or-AT has only 3 car- 
bohydrate sidechains. The evidence obtained for the 
attachment point of each of these sidechains is sum- 
marised in fig.1. The additional sequence provided by 
the isolation of the glycopeptides along with [2] gives 
a provisional sequence of some 90% of the residues of 
human or-AT. This allows placement of the carbohy- 
drate attachment points within the molecule (tig.2). 
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Fig.1. Sequence of the glycopeptides of a,-antitrypsin. The peptides are shown in order of placement from the N-terminus. Data 
for the C-terminal glycopeptide (c) appeared in [ 21. The position of the peptides in the whole molecule is shown in fig.2. 
GlU-Asp-PrO-Gln-Gly-Asp-Ala-Ala-Gln-Lys-Thr-Asp-Th~-Se~-His-His-Asp-Gl~- 
ASp-HiS-PrO-Thr-Phe-Asn-Lys-Ile-Thr-Pro-Asn-Leu-Al~-Gl"-Ph~-Al~-Ph~-S~~- 
Leu-Tyr-Arg-Gln-Leu-Ala-His-Gln-Ser~Ser-Thr-Asx-Ile-Phe-Phe-Ser-Pro- 
VaI-Ser-..!Y!..-Phe-Ala-Met-Leu-Ser-Leu_s-Al~-Asp-Th~-His-Asp- 
Glu-Ile-LeU-Glu-Gly-Leu-As"-Ph~~L~"-Th~-Gl~-ll~-P~~-Gl~-Al~-Gl~-ll~- 
His-Glu-Gly-Phe-Glu-Glu-Leu-Leu-Arg-Thr-Leu-Asp-Gl~-P~o-As~-se~-Gln-.... 
(~.9)-Phe-LeU-Glu-Asx-Val-His-Lys-Leu-Tyr-His-Ser-Glu-Ala-Phe-Thr-Val-Asx- 
Phe-Gly-Asx-Thr-Glx-Glu-Ala-His-Lys-Glx-Ile-XXX-As~-Ty~-V~l-Gl~-Lys-Gly- 
Thr-G1n-Gly-Lys-..~!l)..-Ala-Leu-Val-Asn-Tyr-Ile-Leu-Phe-Lys-Gly-Lys-T~p- 
Glu-Arg-Pro-Phe-Glu-Val-Lys-Asp-Thr-Glu-Glu-Glu-A~p-Phe-His-Val-Asp-Gln- 
Val-Thr-Thr-Val-Lys-Val-Pro-Met-Met-Lys-Arg-Leu-Gly-Met-Phe-Asn-Ile-Gln- 
His-Cys-Lys-Lys-XXX XXX-SW-Trp-Val-Leu-Leu-Met-Lys-Tyr-La-GlymAla- 
Thr-Ala-Ile-Phe-Phe-Leu-Pro-Asp-Glu-Gly-Lys-Leu-Gln-His-Leu-Glu-Asn-Glu- 
Leu-Thr-His-Asp-Ile-Ile-Thr-Lys-Phe-Leu-Glu-Asn-Gl~-Asp-A~g-Arg-ser-Ala- 
Ser-Leu-HiS-Leu-Pro-Lys-Leu-Ser-Ile-Thr-Gly-Thr-Tyr-Asp-Leu-Lys-Ser-Val- 
Leu-Gly-Gln-Leu-Gly-Ile-Thr-Lys-Val-Phe-Ser-Asn-Gly-Al~-Asp-Le~-Se~-Gly- 
Val-Thr-Glu-Glu-Ala-Pro-Leu-Lys-Leu-Ser-Lys-Ala-Val-His-Lys-Ala-Val-Leu- 
Thr-Ile-Asp-Glu-Lys-Gly-Thr-Glu-Ala-Ala-Gly-Ala-~t-Phe-Leu-Glu-Ala-Ile- 
Pro-Met-Ser-Ile-Pro-Pro-Glu-Val-Lys-Phe-Asn-Lys-P~~-Ph~-V~l-Ph~-Le"-Met- 
Ile-Glu-Gln-Asn-Thr-Lys-Ser-Pro-Leu-Phe-~t-Gly-Lys-Val-Val-Asn-Pro-Thr- 
Gln-Lys 
Fig.2. Carbohydrate attachment sites: 90% of the sequence 
of human o,-AT is provided by the 4 polypeptide fragments 
above, positioned by homology with antithrombin-III and 
ovalbumin. The composition but not the sequence of the 
intervening peptides has been determined. Their approximate 
lengths, as deduced from homologies are indicated by the 
bracketed figures. Carbohydrate attachment sites are boxed. 
The reactive centre is underlined. Sequence and compositional 
analyses exclude a similar centre near the N-terminus. 
A check on the positioning of the attachment 
points was possible because of the close amino acid 
sequence homology of cui-AT with antithrombin-III 
and ovalbumin [2,8,9]. This homology had been 
demonstrated for the C-terminal portion of the mole- 
cule but did not include the initial N-terminal frag- 
ment. However, the extension of sequence of the 
N-terminal fragment shows that a strong homology 
does commence after the 30th residue. The alignment 
of the first 30 residues of or-AT with the first 56 resi- 
dues of antithrombin-III gave a match score below 
the mean for the randomised same-composition, i.e., 
there is no homology. However, alignment of residues 
31-48 of&r-AT with residues 57-75 of antithrombin 
gave an alignment score for the match of 3.24 giving 
p < 0.001 that the similarity was due to chance alone. 
Visual inspection of the aligned sequence of &i-AT, 
antithrombin-III and ovalbumin confirms that the 
homologies extend from residue 3 1 of ori-AT to the 
C-terminus. The homologous sequences allow the car- 
bohydrate attachment points of (ui-AT to be precisely 
positioned in alignment with residues Asp 72, Asp 109 
and Asp 269 of antithrombin-III. 
The structure of the carbohydrate sidechains shows 
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some variation. These results support the findings [ 1 ] 
that the predominant structure is a biantennary side- 
chain but the central attachment site may be occupied 
by a triantennary carbohydrate sidechain. This varia- 
tion in carbohydrate structure, mainly at the central 
attachment point, gives rise to isoforms that explain 
the observed microheterogeneity of a,-AT [6]. 
A number of points could be made in relation to 
the overall sequence of the protein but these can 
await the publication of the definitive structure of 
human or-AT. However, a striking feature at this stage 
is the support given for the placement [5] of the reac- 
tive centre as being 36 residues from the C-terminus 
(fig.2). The sequence gives no support for the claimed 
existence of a similar site near the N-terminus [ 10-131. 
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